{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:01:50Z","timestamp":1782298910669,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.crohns.2009.08.003","type":"journal-article","created":{"date-parts":[[2009,10,10]],"date-time":"2009-10-10T09:20:30Z","timestamp":1255166430000},"page":"102-105","source":"Crossref","is-referenced-by-count":22,"title":["Mesalazine vanishing time from rectal mucosa following its topical administration"],"prefix":"10.1093","volume":"4","author":[{"given":"M.T.","family":"Pimpo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Galletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Viscido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Caprilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Frieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2009.08.003_bib1","first-page":"580","article-title":"A new sulphanilamide preparation. A. therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestation in treatment with Sulfamilamide preparations","volume":"110","author":"Salazopyrin","year":"1942","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.crohns.2009.08.003_bib2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2009.08.003_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.47.3.410","article-title":"Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis","volume":"47","author":"Frieri","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.08.003_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2036.1999.00501.x","article-title":"Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.08.003_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1046\/j.1365-2036.1999.00642.x","article-title":"Rectal and colonic mesalazine concentration in active ulcerative colitis: oral plus topical treatment","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.crohns.2009.08.003_bib6","first-page":"732","article-title":"5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results","volume":"82","author":"Guarino","year":"1987","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.08.003_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dld.2004.09.017","article-title":"Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis","volume":"37","author":"Frieri","year":"2005","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.crohns.2009.08.003_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2036.1995.tb00384.x","article-title":"Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis","volume":"9","author":"Marshall","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.08.003_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-8553(01)00012-7","article-title":"Inflammatory bowel disease: medical therapy for specific clinical presentations","volume":"31","author":"Banerjee","year":"2002","journal-title":"Gastroenterol Clin N Am"},{"issue":"9","key":"10.1016\/j.crohns.2009.08.003_bib10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1365-2036.2000.00784.x","article-title":"Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study","volume":"14","author":"Pokrotnieks","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2009.08.003_bib11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"10.1016\/j.crohns.2009.08.003_bib12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.mib.0000231496.92013.85","article-title":"Clinical guidelines for the medical management of left sided? ulcerative colitis and ulcerative proctitis: summary statement","volume":"12","author":"Regueiro","year":"2006","journal-title":"Infl Bow Disease"},{"issue":"1","key":"10.1016\/j.crohns.2009.08.003_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF02047216","article-title":"Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis","volume":"37","author":"Mantzaris","year":"1994","journal-title":"Dis Col Rectum"},{"issue":"9","key":"10.1016\/j.crohns.2009.08.003_bib14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ibd.20158","article-title":"Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study","volume":"13","author":"Yokoyama","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.crohns.2009.08.003_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study","volume":"42","author":"Marteau","year":"1998","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.crohns.2009.08.003_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00365520310008133","article-title":"Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis","volume":"39","author":"Piodi","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.08.003_bib17","first-page":"41","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"10","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"10.1016\/j.crohns.2009.08.003_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5375.89","article-title":"Variation between observers in describing mucosal appearances in proctocolitis","volume":"1","author":"Baron","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.crohns.2009.08.003_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0731-7085(95)01608-2","article-title":"Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2.5-dihydroxybenzoic acid in endoscopic intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection","volume":"14","author":"Palumbo","year":"1995","journal-title":"J Pharmacol Biomed Annal"},{"issue":"Suppl A","key":"10.1016\/j.crohns.2009.08.003_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.08.003_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.26.4.400","article-title":"Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion","volume":"26","author":"Campieri","year":"1985","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.08.003_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/gut.31.11.1271","article-title":"Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion","volume":"31","author":"Staerk Laursen","year":"1990","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.crohns.2009.08.003_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2036.2003.01409.x","article-title":"Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500mg suppositories to healthy volunteers and ulcerative proctitis patients","volume":"17","author":"Aumais","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.crohns.2009.08.003_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00054725-200108000-00007","article-title":"Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalazine and sulfasalazine","volume":"7","author":"Naganuma","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2009.08.003_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/00365529108996497","article-title":"Availability of mesalazine (5-Aminosalicylic acid) from enemas and suppositories during steady-state conditions","volume":"26","author":"Jacobsen","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.crohns.2009.08.003_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2125.2000.00164.x","article-title":"Dose loading with delayed-release mesalamine: a study of tissue drug concentration and standard pharmacokinetic parameters","volume":"49","author":"Hussain","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.crohns.2009.08.003_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.crohns.2009.08.003_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/4\/1\/102\/1119927\/4-1-102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:44:47Z","timestamp":1503449087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.08.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1873994609000932"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.08.003","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}